| ||
| Antisoma CEO and finance director leave after pipeline failures ... And just over a year ago Antisoma was also forced to discontinued development of ASA404 in late-stage non-small cell lung cancer (NSCLC), after the drug failed to show a survival benefit in the Phase III ATTRACT-1 trial. ... thepharmaletter.com - http://www.thepharmaletter.com/ | ||
| LungBlog : A Breath Away From The Cure » Blog Archive » Fish Oil ... By sam In the study, researchers at the University of Alberta in Edmonton, Canada, enrolled 40 patients with non-small-cell lung cancer. They were all in the early stages of treatment. Sixteen of those patients took 2.2 grams of fish oil per ... LungBlog : A Breath Away From The Cure - http://www.lungblog.com/ | ||
| Fish Oil Helps Cancer Patients Maintain Muscle Mass By Ramona Bates MD Vera C. Mazurak, PhD, of the University of Alberta in Edmonton, and colleagues reported the findings of their small study online February 28, 2011 in the journal Cancer. Forty patients with nonsmall cell lung cancer receiving 10 weeks ... Emaxhealth - http://www.emaxhealth.com/ |
| ||
| Titan Study Shows Erlotinib to be as Effective as Chemotherapy in ... The open-label study included 424 patients whose lung cancer had ... patients with advanced non-small-cell lung cancer (NSCLC) and poor prognosis: efficacy ... oncozine.ning.com/profiles/.../titan-study-shows-erlotinib-to | ||
| Serum thymidine kinase 1 is a prognostic and monitoring factor in ... 更多>> Serum thymidine kinase 1 is a prognostic and monitoring factor in prtients with non-small cell lung cancer 在非小细胞肺癌患者中,血清胸苷激酶1可 作为一 ... wenku.baidu.com/view/e302ada7f524ccbff1218419.html | ||
| Protocol Table 9801, A Phase III Study of Amifostine Mucosal Protection For Patients With Favorable Prognosis Inoperable Stage II-IIIA/B Non-Small Cell Lung Cancer (NSCLC ) ... www.rtog.org/ClinicalTrials/ProtocolTable.aspx |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment